Schedule I

Schedule I is the most restrictive classification tier in the United States Controlled Substances Act (CSA) of 1970, a federal statute administered jointly by the Drug Enforcement Administration and the Food and Drug Administration. It groups substances the statute treats as meeting three criteria: a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision.

These are legal standards, not scientific findings. "No currently accepted medical use" is a term of art with a specific administrative meaning — it is not equivalent to "no published clinical evidence."

The numeral does not travel across legal systems. Canada has its own schedule framework under the Controlled Drugs and Substances Act, where Schedule I covers different substances under different criteria. United Nations drug treaties carry their own Schedule I designations with unrelated meanings. A schedule number that signals the most restrictive tier in one system may occupy an ordinary position in another.

What it means in practice

A substance reaches Schedule I either by direct congressional action — as heroin did in the original 1970 Act — or through DEA rulemaking following an FDA medical-use evaluation. The DEA also holds emergency scheduling authority allowing temporary placement when it finds an imminent public safety hazard, a mechanism applied frequently to novel synthetic compounds.

Once placed in Schedule I, prescribing is not permitted under federal law. Research requires a DEA Schedule I researcher registration, a more administratively intensive process than clearance for lower-schedule work. The Federal Analogue Act of 1986 extends Schedule I treatment to chemical analogues of Schedule I or II substances when those analogues are intended for human consumption, so the effective scope of the list reaches beyond its named entries.

Rescheduling requires a formal petition, an FDA scientific and medical evaluation, and DEA rulemaking — a process that has historically taken years to complete.

How jurisdictions vary

The label "Schedule I" appears in other national drug laws but describes different tiers and different substances. Canada's Controlled Drugs and Substances Act has its own Schedule I, covering substances under Canadian criteria that do not correspond to US placements; many compounds that are US Schedule I appear in lower Canadian tiers.

Australia uses Schedule 9 (Prohibited Substances) as its most restrictive tier under the Therapeutic Goods Act; the system does not include a "Schedule I." The United Kingdom organises controlled drug law under a Class A/B/C framework with no numbered schedules.

The United Nations treaties — the Single Convention on Narcotic Drugs (1961) and the Convention on Psychotropic Substances (1971) — each carry their own four-schedule systems whose numbers do not correspond to United States schedule numbers. The same substance may appear in different positions across each treaty.

What is contested

The statutory phrase "no currently accepted medical use" has produced documented tension between administrative placement and clinical research findings. Psilocybin and MDMA both received FDA Breakthrough Therapy Designation — a status the FDA issues when preliminary clinical evidence suggests a compound may offer substantial improvement over available treatments — while remaining in Schedule I. Active DEA proceedings concerning the status of both compounds were underway as of 2024–2025.

Cannabis has been the subject of formal rescheduling petitions for decades. In 2023, the Department of Health and Human Services recommended rescheduling to Schedule III; the DEA opened a formal rulemaking proceeding in 2024. It remained in Schedule I under federal law as of this writing. The entry reports the classification's status; the divergence between the administrative standing and the published clinical record is a matter of fact in the public record.

Scope and currency

This entry describes the general structure of the United States Schedule I classification and does not constitute legal advice. It does not describe the law as it applies to any reader's jurisdiction, circumstances, or conduct. This entry states the position as of August 2026.

For the legal status of a specific substance — including its current federal schedule, state-level variations, and international placement — see the Legal Status section of that substance's page, which carries its own jurisdiction, date, and cited source.